AASLD Releases Updated Practice Guidance on Semaglutide (Wegovy) for MASH

The American Association for the Study of Liver Diseases (AASLD) has released an updated practice guidance on semaglutide (Wegovy) therapy for metabolic dysfunction-associated steatohepatitis (MASH).^1,2

The November 7, 2025, practice…